Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?

Pediatric nephrology (Berlin, Germany) - 1 Jul 2019

Prytuła Agnieszka, Cransberg Karlien, Raes Ann

Abstract excerpt

CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin D. In this review, we summarize the clinical aspects of CYP3A-mediated metabolism of tacrolimus and vitamin D with emphasis on the influence of single-nucleotide polymorphisms on tacrolimus disposition. We describe the utility of 4β hydroxycholesterol as a marker of CYP3A activity. Then, we discuss the possible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Density
Share to Bone Diseases, Metabolic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calcineurin Inhibitors

Share to Cytochrome P-450 CYP3A

Share to Hydroxycholesterols

Share to Kidney Transplantation

Share to Tacrolimus

Share to Vitamin D

Source

Identifiers

PMID: 30058048
DOI: 10.1007/s00467-018-4030-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?PMID 30058048Read ↗

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.Semantic proximity Read ↗

Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and CancerSemantic proximity Read ↗

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.Semantic proximity Read ↗

Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.Semantic proximity Read ↗

Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipientsSemantic proximity Read ↗

ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenetics of calcineurin inhibitors in renal transplantation.Semantic proximity Read ↗

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Semantic proximity Read ↗

The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.Semantic proximity Read ↗

The Pharmacogenetics of Calcineurin Inhibitors: One Step Closer Toward Individualized Immunosuppression?Semantic proximity Read ↗

Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.Semantic proximity Read ↗

CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.